Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region

The Pharmacogenomics Journal volume 9, pages 103–110 (2009)Cite this article

Abstract

RGS2 (regulator of G-protein signaling 2) modulates dopamine receptor signal transduction. Functional variants in the gene may influence susceptibility to extrapyramidal symptoms (EPS) induced by antipsychotic drugs. To further investigate our previous report of association of the RGS2 gene with susceptibility to antipsychotic-induced EPS, we performed a replication study. EPS were rated in 184 US patients with schizophrenia (115 African Americans, 69 Caucasian) treated for at least a month with typical antipsychotic drugs (n=45), risperidone (n=46), olanzapine (n=50) or clozapine (n=43). Six single nucleotide polymorphisms (SNPs) within or flanking RGS2 were genotyped (rs1933695, rs2179652, rs2746073, rs4606, rs1819741 and rs1152746). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. Our results indicate association of SNP rs4606 with antipsychotic-induced parkinsonism (AIP), as measured by the Simpson Angus scale, in the overall sample and in the African-American subsample, the G (minor) allele having a protective effect. ORs for AIP among rs4606 G-allele carriers were 0.23 (95% CI 0.10–0.54, P=0.001) in the overall sample, and 0.20 (0.07–0.57, P=0.003) in the African-American subsample. In the previously studied Israeli sample the OR was 0.31 (0.11–0.84, P=0.02). We completely sequenced the RGS2 gene in nine patients with AIP and nine patients without, from the Israeli sample. No common coding polymorphisms or additional regulatory variants were revealed, suggesting that association of the rs4606 C/G polymorphism with AIP is biologically meaningful and not a consequence of linkage disequilibrium with another functional variant. Taken together, the findings of the current study support the association of RGS2 with AIP and focus on a possible protective effect of the minor G allele of SNP rs4606. This SNP is located in the 3′-regulatory region of the gene, and is known to influence RGS2 mRNA levels and protein expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Blanchet PJ . Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30 (Suppl 1): S101–S107.

    Article  PubMed  Google Scholar 

  2. Reynolds GP . Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18: 340–345.

    Article  CAS  PubMed  Google Scholar 

  3. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M . Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084–1089.

    Article  CAS  PubMed  Google Scholar 

  4. Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB . Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry 2005; 187: 137–142.

    Article  PubMed  Google Scholar 

  5. Hirose G . Drug induced parkinsonism: a review. J Neurol 2006; 253 (Suppl 3): iii22–iii24.

    Google Scholar 

  6. Lerner V, Libov I, Kapstan A, Miodownik C, Dwolatzky T, Levine J . The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 2007; 44: 20–28.

    PubMed  Google Scholar 

  7. Arranz MJ, de Leon J . Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707–747.Jun 5; e-pub ahead of print.

    Article  CAS  PubMed  Google Scholar 

  8. Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O et al. Association of the RGS2 gene with extrapyramidal symptoms (EPS) induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519–528.

    Article  CAS  PubMed  Google Scholar 

  9. Semplicini A, Lenzini L, Sartori M, Papparella I, Calò LA, Pagnin E et al. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. J Hypertens 2006; 24: 1115–1124.

    Article  CAS  PubMed  Google Scholar 

  10. Hollinger S, Hepler JR . Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002; 54: 527–559.

    Article  CAS  PubMed  Google Scholar 

  11. Taymans JM, Leysen JE, Langlois X . Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem 2003; 84: 1118–1127.

    Article  CAS  PubMed  Google Scholar 

  12. Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal 2004; 16: 711–721.

    Article  CAS  PubMed  Google Scholar 

  13. Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol Chem 2004; 279: 21248–21256.

    Article  CAS  PubMed  Google Scholar 

  14. Potenza MN, Gold SJ, Roby-Shemkowitz A, Lerner MR, Nestler EJ . Effects of regulators of G protein-signaling proteins on the functional response of the mu-opioid receptor in a melanophore-based assay. J Pharmacol Exp Ther 1999; 291: 482–491.

    CAS  PubMed  Google Scholar 

  15. Yalcin B, Willis-Owen SA, Fullerton J, Meesaq A, Deacon RM, Rawlins JN et al. Genetic dissection of a behavioral quantitative trait locus shows that Rgs2 modulates anxiety in mice. Nat Genet 2004; 36: 1197–1202.

    Article  CAS  PubMed  Google Scholar 

  16. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003; 111: 445–452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Leygraf A, Hohoff C, Freitag C, Willis-Owen SA, Krakowitzky P, Fritze J et al. Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm 2006; 113: 1921–1925.

    Article  CAS  PubMed  Google Scholar 

  18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225–2229.

    Article  CAS  Google Scholar 

  19. Chen JM, Férec C, Cooper DN . A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006; 120: 1–21.

    Article  CAS  PubMed  Google Scholar 

  20. Casey DE . Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65 (Suppl): 25–28.

    CAS  PubMed  Google Scholar 

  21. Miyamoto S, Duncan GE, Marx CE, Lieberman JA . Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79–104.

    Article  CAS  PubMed  Google Scholar 

  22. Ho G, Wang Y, Jones PG, Young KH . Activation of serum response element by D2 dopamine receptor is governed by Gbetagamma-mediated MAPK and Rho pathways and regulated by RGS proteins. Pharmacology 2007; 79: 114–121.

    Article  CAS  PubMed  Google Scholar 

  23. Stanwood GD, Parlaman JP, Levitt P . Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G-protein signalling (RGS) transcripts. Eur J Neurosci 2006; 24: 806–818.

    Article  PubMed  Google Scholar 

  24. Taymans JM, Kia HK, Groenewegen HJ, Leysen JE, Langlois X . Bilateral control of brain activity by dopamine D1 receptors: evidence from induction patterns of regulator of G protein signaling 2 and c-fos mRNA in D1-challenged hemiparkinsonian rats. Neuroscience 2005; 134: 643–656.

    Article  CAS  PubMed  Google Scholar 

  25. Tovey SC, Willars GB . Single-cell imaging of intracellular Ca2+ and phospholipase C activity reveals that RGS 2, 3, and 4 differentially regulate signaling via the Galphaq/11-linked muscarinic M3 receptor. Mol Pharmacol 2004; 66: 1453–1464.

    Article  CAS  PubMed  Google Scholar 

  26. Robinet EA, Geurts M, Maloteaux JM, Pauwels PJ . Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA. Neurosci Lett 2001; 307: 45–48.

    Article  CAS  PubMed  Google Scholar 

  27. Fatemi SH, Reutiman TJ, Folsom TD, Bell C, Nos L, Fried P et al. Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique. Neuropsychopharmacology 2006; 31: 1888–1899.

    Article  CAS  PubMed  Google Scholar 

  28. Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A . Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005; 8: 183–194.

    Article  CAS  PubMed  Google Scholar 

  29. Kay S, Fiszbein A, Opler LA . The Positive And Negative Syndrome scale for schizophrenia. Schizophr Bull 1987; 13: 261–276.

    Article  CAS  PubMed  Google Scholar 

  30. Simpson G, Angus MP . Scale for assessment extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11–19.

    Article  CAS  Google Scholar 

  31. Barnes TR . A rating scale for drug induced akathisia. Br J Psychiatry 1989; 154: 672–676.

    Article  CAS  PubMed  Google Scholar 

  32. Rozen S, Skaletsky H . Primer3 on the WWW for general users and for biologist programmers.In: Krawetz S, Misener S (eds). Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000. Humana Press: Totowa, NJ.pp. 365–386.

    Google Scholar 

  33. Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stephens M, Donnelly P . A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162–1169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported in part by internal funds from Hadassah Medical Organisation (to BL) and by an Independent Investigator Grant from Eli Lily (to RCS).

Author information

Authors and Affiliations

  1. Department of Psychiatry, Biological Psychiatry Laboratory, Hadassah–Hebrew University Medical Center, Jerusalem, Israel

    L Greenbaum, A Rigbi, O Teltsh, K Kanyas & B Lerer

  2. Department of Psychiatry, New York University Medical School, New York, NY, USA

    R C Smith

  3. Manhattan Psychiatric Center, New York, NY, USA

    R C Smith

  4. Beer Yaakov Mental Health Center, Beer Yaakov, Israel

    R Strous

  5. Center for Genomic Technologies, Hebrew University, Jerusalem, Israel

    M Korner

  6. Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

    D Lancet & E Ben-Asher

Authors
  1. L Greenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R C Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Rigbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Strous
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Teltsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Kanyas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Korner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Lancet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Ben-Asher
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Lerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Lerer.

Additional information

Duality of interest

The authors have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greenbaum, L., Smith, R., Rigbi, A. et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region. Pharmacogenomics J 9, 103–110 (2009). https://doi.org/10.1038/tpj.2008.6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2008.6

Keywords

This article is cited by

Search

Advanced search

Quick links